Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEGIS-I: Safety and Tolerability of CSL112 in Acute Myocardial Infarction
NCT02108262Phase 2Completed
- Sponsor
- CSL Limited
- Start
- Aug 2014
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
A Phase 2 trial of CSL112 in acute myocardial infarction (AMI), sponsored by CSL Limited. Started Aug 2014; status: completed.
02
Drugs
CSL112
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT02108262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02108262.